Surgery in the renal transplant patient

Similar documents
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol

Date: 23 June Context and policy issues:

Perioperative use of angiotensin blockade

Transplantation in Australia and New Zealand

By the way, I have a transplant..

Postoperative monitoring after

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

How to improve long term outcome after liver transplantation?

1. Discuss the basic pathophysiology of end-stage liver and kidney failure.

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions

BK Virus (BKV) Management Guideline: July 2017

Overview of New Approaches to Immunosuppression in Renal Transplantation

Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

Surgical antibiotic prophylaxis at Epworth Healthcare

REACH Risk Evaluation to Achieve Cardiovascular Health

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya

Chapter 6: Transplantation

BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

Common pitfalls in kidney transplant patients. (for the non-nephrologist)

Management of Post-transplant hyperlipidemia

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.

Patients with previous organ transplant

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital

Long-term complications after kidney transplantation. Adnan Sharif

Nephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients

Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Targeted Adverse Event (ADV)

This study is currently recruiting participants.

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481

OBJECTIVES. Phases of Transplantation and Immunosuppression

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

Measure Information Form

Cases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center

How do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK?

THE KIDNEY AND SLE LUPUS NEPHRITIS

Caring for Australians with Renal Impairment. BP lowering and CVD

Cover Page. The handle holds various files of this Leiden University dissertation.

EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland

Vice Dean and Professor of Medicine

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania

Targeted Adverse Event (ADV)

CHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping

Acute Kidney Injury (AKI) Undergraduate nurse education

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

CHAPTER 14. Renal Transplantation

Clinical pathological correlations in AKI

Chapter 22: Hematological Complications

OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS

Cover Page. The handle holds various files of this Leiden University dissertation.

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older)

National Vascular Registry

The role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital

Emerging Drug List EVEROLIMUS

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

Preoperative tests (update)

Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.

Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care

Clinical guidance for the management of. Cytomegalovirus (CMV) in. kidney/pancreas transplant patients. Guidance prepared by Cardiff and Vale UHB

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker

Dr A Pokrajac MD MSc MRCP Consultant

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

The in-hospital management of COPD-exacerbation includes three core processes:

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

2016 Re-Audit of Patient Blood Management in adults undergoing elective, scheduled surgery

Pembrozulimab Induced Collagenous Colitis. Mokshya Sharma 1, MD, Santhosh Ambika 2, MD University of Nevada, Reno SOM

Kidneytransplant pathologyrelatedto immunosuppressiveagents

Analysis of the Results of ABO-Incompatible Kidney Transplantation: In Comparison with ABO-Compatible Kidney Transplantation

clevelandclinic.org/transplant

IgA Nephropathy - «Maladie de Berger»

Blood Pressure Treatment Goals

Indications for Antibiotic Prophylaxis

Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong

valganciclovir, 450mg tablets, 50mg/ml powder for oral solution (Valcyte ) SMC No. (662/10) Roche Products Ltd

Preoperative tests (update)

How to Address an Inappropriately high Mortality Rate? Joe Sharma, MD Associate Professor of Surgery NSQIP Surgical Champion

OHSU Digital Commons. Oregon Health & Science University. Tysen June Cullen. Scholar Archive. September 2012

Innovative Practice: Compliance contracts for Transplant. Anne Suhr, RD, CD DSI, Inc Indianapolis, IN

Topic BKV Polyoma Virus

Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients

Acute Kidney Injury for the General Surgeon

BCCA Protocol for Primary Treatment of Metastatic or Recurrent Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel

Special Situations 1

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)

Transcription:

Surgery in the renal transplant patient

Prevalence of renal transplants in Australia

Prevalence according to State/Territory

Overall patient and graft survival following renal transplantation: short term

Overall patient and graft survival following renal transplantation: long term

Important patient factors Transplant patients have a high cardiovascular risk and higher cardiovascular event rate Patients have a higher overall infection risk Patients at risk of steroid myopathy if on high dose Increased risk of acute kidney injury

Medication factors mtor inhibitors are associated with impaired wound healing Changes to medication put the patients at risk of rejection Tacrolimus/cyclosporine effected by inhibitors/enhancers of CYP450 system

Patient factors: Cardiac disease

Patient factors: infection Renal transplant patients undergoing CABGS have an infectious complication rate of 10-20% Review of 1939 patients after renal transplantation revealed wound infection in 7.5%, with most being superficial. Obesity and diabetes remain strong risk factors

Hypogammaglobulinaemia is common Am J Transplant. 2013 Oct;13(10):2601-10 Meta-analysis of 1756 solid organ transplants with IgG levels at one year -IgG < 700mgl 40% -IgG < 400mg/l 15% OR Respiratory infection 4.83 if IgG <400mg/l

Hypogammaglobulinaemia in renal transplants Small number of studies show no benefit in giving IVIG prophylaxis in the absence of recurrent infections Patients with recurrent infections and IgG < 400mg/l may be treated with IVIG

Patient factors: increased risk of acute kidney injury From 27,232 patients transplanted 1995-2000, 4181 admissions for AKI with dialysis needed in 14% Am J Kidney Dis. 2012 Apr;59(4):558-65 Animal models reveal a loss of autoregulation of renal blood flow after transplant Tacrolimus associated with arteriolosclerosis Many will have renal impairment and be on angiotensin blockade

Wound-healing is impaired after kidney transplantation with mtor inhibitors Transplantation. 2004 May 27;77(10):1555-61. RCT of tacrolimus vs sirolimus 59 Tacrolimus 8% wound complications 64 Sirolimus 47% wound complication 35% if BMI < 30

Wound-healing is impaired after kidney transplantation with mtor inhibitors Impaired wound healing is influenced by: -mtor inhibitor dose -prednisolone -patients overall risk Non-obese patient on low dose of both mtor and prednisolone is low risk May consider mtor switch in a high risk patient

Typical regimen in a renal transplant patient Mycophenolate 500mg bd Tacrolimus bd; according to blood levels Prednisolone 5mg/day

Clinical Scenario 1 65 year old man having hip replacement for avascular necrosis of the hip. He received a transplant 2007, having had glomerulonephritis. He is well, without symptoms of heart disease. He takes mycophenolate, tacrolimus, and prednisolone 5mg/d. He also takes irbesartan and atorvastatin. His creatinine is 150 micromol/l, and Hb is 128. Withhold irbesartan the day of surgery Hydrocortisone intraoperatively Restart mycophenolate and tacrolimus that evening orally

Clinical Scenario 2 70 year old woman, with recurrent infections, on IVIG. Renal transplant 2012, T2DM, HT, creatinine 190. Takes mycophenolate, tacrolimus, prednisolone (5mg/d), Ramipril, and amlodipine. Having laparoscopic cholecystectomy Consider cardiac scan in pre-operative assessment Admit the day before withholding Ramipril and starting iv fluid Intraoperative hydrocortisone and continue post-operatively Commence iv mycophenolate and tacrolimus on the day of surgery

Summary With pre-operative assessment and post-operative medication plan, well selected stable renal transplant patients can easily undergo surgery Standard patient factors such as obesity, chronic renal failure, diabetes and vascular comorbidities are of greater importance than transplant medication in terms of their peri-operative impact. In patients where there is an expectation of being unable to take oral medication for more than 24 hours, intravenous transplant medication should be commenced postoperatively. Sirolimus/Everolimus mainly associated with wound/operative complications in thoracotomy, or when mtor and prednisolone are high dose. In the cases of cardiac surgery consider a switch to tacrolimus at the time of surgery.

Epworth HealthCare 21